Editas Medicine Quarterly Income Statement
NASDAQ: EDITHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Editas Medicine revenue and earnings
In the quarter ended Sep 30, 2026, Editas Medicine generated $10.4 million in revenue, up 37.4% from the same quarter a year earlier. Editas Medicine reported a net loss of $23.4 million, compared with a loss of $25.1 million a year earlier. Operating margin was -234.3%.
Diluted earnings per share came in at -$0.15.
Summary generated from market data by MetaCap's automated system. Methodology
Editas Medicine income statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.37M | 11.89M | 2.83M | 24.74M | 7.54M | 3.58M | 4.66M | 30.60M | 61.00K | 513.00K | 1.14M | 60.05M |
| Revenue growth (YoY) | +37.41% | +232.31% | -39.22% | -19.16% | +12265.57% | +597.47% | +310.40% | -49.03% | -98.86% | -82.23% | -88.48% | +818.74% |
| Operating Expenses | 34.65M | 30.44M | 27.83M | 32.50M | 32.09M | 55.12M | 80.82M | 77.20M | 65.73M | 72.42M | 68.13M | 84.01M |
| Research & Development | 21.17M | 20.18M | 17.60M | 27.40M | 19.77M | 16.18M | 26.59M | 48.61M | 47.64M | 54.21M | 48.79M | 69.56M |
| Operating Income | -24.28M | -18.55M | -25.00M | -7.75M | -24.55M | -51.54M | -76.16M | -46.59M | -65.67M | -71.90M | -66.99M | -23.96M |
| Interest Expense | 0 | 0 | 5.00M | 0 | 0 | 0 | 2.13M | 2.19M | 0 | 0 | 0 | — |
| Other Income (Expense) | 889.00K | 324.00K | 21.00K | 2.13M | -569.00K | -1.69M | 75.00K | 1.20M | 3.52M | 4.30M | 5.04M | 5.09M |
| Net Income | -23.39M | -18.23M | -24.98M | -5.62M | -25.12M | -53.23M | -76.09M | -45.40M | -62.14M | -67.61M | -61.95M | -18.87M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.15 | -0.15 | -0.26 | 0.03 | -0.28 | -0.63 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.20 |
| EPS (Diluted) | -0.15 | -0.15 | -0.26 | 0.03 | -0.28 | -0.63 | -0.92 | -0.55 | -0.75 | -0.82 | -0.76 | -0.20 |
| Shares Outstanding (Basic) | 153.60M | 119.29M | 97.88M | — | 90.09M | 84.41M | 83.06M | — | 82.49M | 82.31M | 81.94M | — |
| Shares Outstanding (Diluted) | 153.60M | 119.29M | 97.88M | — | 90.09M | 84.41M | 83.06M | — | 82.49M | 82.31M | 81.94M | — |
| EBITDA | -23.90M | -18.14M | -24.52M | -6.95M | -23.83M | -49.71M | -74.25M | -45.21M | -64.07M | -70.48M | -65.58M | -22.50M |
| Operating Margin | -234.27% | -156.05% | -883.19% | -31.34% | -325.44% | -1440.58% | -1635.10% | -152.24% | -107649.18% | -14016.18% | -5902.29% | -39.90% |
| Net Margin | -225.69% | -153.32% | -882.44% | -22.72% | -332.98% | -1487.84% | -1633.49% | -148.33% | -101870.49% | -13178.75% | -5458.15% | -31.43% |
This table shows 12 quarterly periods of Editas Medicine's income statement, from Q3 2026 back to Q4 2023, across 14 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow EDIT's reporting calendar. What is a income statement?